The overall Objective of Biospecimens Accessioning and Processing Shared Resource (BAP) is to provide a central facility to electronically accession and process biospecimens intended for research by Cancer Center members.
The Specific Aims of the Shared Resource are to 1) provide electronic accessioning of biospecimens into a central Research Specimen Database, 2) to process the specimens appropriately according to their projected end use, 3) to provide nucleic acid extraction services, 4) to provide cryopreservation of mononuclear cells and EBV immortalization of B lymphocytes, and 5) to provide consultative services and specific expertise to Cancer Center investigators. Biospecimens accessioned through this resource include solid tissues as well as whole blood and other body fluids. Blood specimens are processed for nucleic acid extraction, future or immediate EBV immortalization of mononuclear cells, and/or frozen storage as plasma, serum or buffy coats. Fresh solid tissues are dissected and frozen in liquid nitrogen or freezing medium. One of the most valuable contributions of the BAP resource is the specimen annotation that is entered into the Research Laboratory Information System at the time of specimen accessioning and subsequently utilized for timely and appropriate retrieval of archived specimens. During the current funding period, BAP has developed substantial automation which has increased sample capacity without increased cost to investigators. Together, the electronic biospecimen accessioning combined with basic specimen processing, EBV immortalization, and nucleic acid extraction services have created a powerful, synergistic Shared Resource critical for support of translations!, epidemiologic and basic research of Cancer Center members. In 2007, the BAP Shared Resource processed over 1,700 cryopreservations and EBV transformations and extracted DNA from over 10,000 biospecimens for over 30 Cancer Center investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-37
Application #
8320366
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-03-01
Budget End
2012-02-29
Support Year
37
Fiscal Year
2011
Total Cost
$164,092
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066

Showing the most recent 10 out of 1129 publications